INTRODUCTION

Up to 246,000 people in the US are estimated to have an ILD

IPF is one of the most common ILDs3

IPF is estimated to affect about 140,000 people in the US. 3-5 years median survival.

Risk factors in patients with IPF5

  • Male gender
  • Older age
  • History of smoking
  • Microbial agents
  • Environmental exposures
  • Family history

ILD is a common, often early, and potentially fatal manifestation in autoimmune diseases6

Up to 30% of patients with RA develop ILD. 39% of patients with RA-ILD may die within 5 years.

Risk factors in patients with RA

  • 4x greater risk in males vs females10
  • Typically occurs in people 40-50 years of age11
  • History of smoking11
  • Rheumatoid factor or anti-CCP antibody11

ILD is a common, often early, and potentially fatal manifestation in autoimmune diseases6

Up to 80% of patients with SSc develop ILD. 18% of patients with SSc-ILD may die within 5 years.

Risk factors in patients with SSc

  • Older age15
  • Male gender15
  • Short disease duration16
  • Diagnosis of dcSSc17
  • Presence of ATA18

*Estimate calculated based on overall ILD prevalence of 74.3 cases per 100,000 in the US, and an overall run-up population of 330.5 million in the US.1,2

References:
1. Wijsenbeek M, Cottin V. N Engl J Med. 2020;383:958-968. 2. Monthly Population Estimates for the United States: April 1, 2020 to December 1, 2022 (NA-EST2021-POP). US Census Bureau, Population Division; 2021. 3. Oldham JM, Noth I. Respir Med. 2014;108(6):819-829. 4. Raghu G et al. Am J Respir Crit Care Med. 2006;174(7):810-816. 5. Raghu G et al; on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2011;183(6):788-824. 6. Fischer A, Distler J. Clin Rheumatol. 2019;38(10):2673-2681. 7. Geerts S et al. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(4):326-335. 8. Shaw M et al. Eur Respir Rev. 2015;24(135):1-16. 9. Hyldgaard C et al. Respirology. 2017;22(3):494-500. 10. Esposito AJ et al. Clin Chest Med. 2019;40(3):545-560. 11. Koo SM et al. Tuberc Respir Dis (Seoul). 2019;82(4):285-297. 12. Fischer A et al. Arthritis Rheumatol. 2019;71(2):182-195. 13. Khanna D et al. Am J Respir Crit Care. 2020;201(6):650-660. 14. Hoffmann-Vold AM et al. Am J Respir Crit Care Med. 2019;200(10):1258-1266. 15. Cappelli S et al. Eur Respir Rev. 2015;24(137):411-419. 16. Steen V. Ann Rheum Dis. 2003;62(2):97-99. 17. Walker UA et al. Ann Rheum Dis. 2007;66(6):754-763. 18. Assassi S et al. Arthritis Res Ther. 2010;12(5):R166.